Suppr超能文献

西班牙马略卡岛乳腺癌按分期、分级和分子分型的生存率

Survival of Breast Cancer by Stage, Grade and Molecular Groups in Mallorca, Spain.

作者信息

Pascual Maria Clara, Montaño Juan José, Franch Paula, Sánchez-Contador Carmen, Ramos Maria

机构信息

Department of Psychology, University of Balearic Islands (UIB), 07122 Palma, Spain.

Health Research Institute of the Balearic Islands (IdISBa), 07120 Palma, Spain.

出版信息

J Clin Med. 2022 Sep 27;11(19):5708. doi: 10.3390/jcm11195708.

Abstract

The aims of this study are: (1) to determine cause-specific survival by stage, grade, and molecular groups of breast cancer, (2) to identify factors which explain and predict the likelihood of survival and the risk of dying from this cancer; and (3) to find out the distribution of breast cancer cases by stage, grade, and molecular groups in females diagnosed in the period 2006-2012 in Mallorca (Spain). We collected data regarding age, date and diagnostic method, histology, laterality, sublocation, pathological or clinical tumor size (T), pathological or clinical regional lymph nodes (N), metastasis (M) and stage, histologic grade, estrogen and progesterone receptors status, HER-2 expression, Ki67 level, molecular classification, date of last follow-up or date of death, and cause of death. We identified 2869 cases. Cause-specific survival for the entire sample was 96% 1 year after diagnosis, 91% at 3 years and 87% at 5 years. Relative survival was 96.9% 1 year after diagnosis, 92.6% at 3 years and 88.5% at 5 years. The competing-risks regression model determined that patients over 65 years of age and patients with triple negative cancer have worse prognoses, and as stages progress, the prognosis for breast cancer worsens, especially from stage III.

摘要

本研究的目的是

(1)按乳腺癌的分期、分级和分子类型确定特定病因生存率;(2)确定解释和预测生存可能性及死于该癌症风险的因素;(3)查明2006年至2012年期间在西班牙马略卡岛确诊的女性乳腺癌病例按分期、分级和分子类型的分布情况。我们收集了有关年龄、诊断日期和方法、组织学、侧别、亚部位、病理或临床肿瘤大小(T)、病理或临床区域淋巴结(N)、转移情况(M)及分期、组织学分级、雌激素和孕激素受体状态、HER-2表达、Ki67水平、分子分类、最后随访日期或死亡日期以及死亡原因的数据。我们确定了2869例病例。整个样本的特定病因生存率在诊断后1年为96%,3年时为91%,5年时为87%。相对生存率在诊断后1年为96.9%,3年时为92.6%,5年时为88.5%。竞争风险回归模型确定,65岁以上患者和三阴性癌症患者预后较差,并且随着分期进展,乳腺癌预后恶化,尤其是从III期开始。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4330/9571737/e31407b1e26d/jcm-11-05708-g001.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验